We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Puretech Health Plc | LSE:PRTC | London | Ordinary Share | GB00BY2Z0H74 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 213.00 | 212.50 | 213.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Home Health Care Services | 23.75M | -50.35M | -0.1839 | -11.58 | 583.33M |
From Apr 2019 to Apr 2024
By Oliver Griffin
PureTech Health PLC (PRTC.LN) said Tuesday that affiliate company Entrega will receive $5 million after entering a research-collaboration agreement with Eli Lilly & Co. (LLY).
Entrega will receive the sum in equity and research funding from Eli Lilly, allowing it to investigate the application of its peptide-delivery technology to Eli Lilly products and therapeutic candidates, PureTech said.
The agreement does not grant Eli Lilly a development or commercialization license for the Entrega technology, PureTech added.
Shares in PureTech Health at 0949 GMT were up 4%, or 5 pence, at 145.00 pence.
Write to Oliver Griffin at oliver.griffin@dowjones.com
(END) Dow Jones Newswires
December 19, 2017 05:15 ET (10:15 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Puretech Health Chart |
1 Month Puretech Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
